Regeneron has declined 26.5% over this time frame, while the broader S&P 500 Index has soared 20.7%. Moreover, the stock is down 1.7% on a YTD basis, compared to SPX’s 2.2% gain during the same ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst ...

Debt Management: Regeneron Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.1. The Significance of Analyst Ratings Explained ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Bernstein cuts Regeneron stock price target to $1,000, keeps Outperform. 3mo. ... REGN) to $1,000 from the previous $1,070, while retaining an Outperform rating on the stock.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings within the last quarter: According to 13 analyst offering 12-month price targets in the last 3 months, Regeneron ...

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years. Learn more on REGN stock here.

Regeneron Pharmaceuticals, Inc. (REGN) is a leading American biotechnology company headquartered in Tarrytown, New York. Valued at $52.9 billion by market cap, the company focuses on discovering ...